Kyntra Bio, Inc. — Form 8-K Summary
Reporting date: September 30, 2026. This current report covers board changes and a change-in-control and severance agreement. Kyntra Bio is a Delaware company focused on developing therapies in oncology and rare disease; its common stock trades on Nasdaq under KYNB.
Board and executive arrangements
- Effective October 1, 2026, Andrew E. Singer, MBA, was appointed a Class III director and Audit Committee member. His term expires in 2029. He will receive non-employee director compensation under the company’s policy; the filing gives no amount.
- Maykin Ho, Ph.D., resigned from the board effective September 30, 2026. The company stated her departure was not due to a disagreement with the company or management.
- On September 30, 2026, the company entered into a new three-year Change in Control and Severance Agreement with CEO Thane Wettig, replacing the prior agreement set to expire October 2, 2026. The new agreement ends October 2, 2029, retains substantially the same terms, and makes no material changes to compensation or benefits. Details of the benefits are incorporated by reference to the company’s July 25, 2023 Form 8-K.
Financial performance and outlook
This filing does not report revenue, profit, cash flow, margins, debt, liquidity, or other operating results, and provides no financial guidance or outlook.
Investor items to verify
- Review the referenced July 25, 2023 Form 8-K for the specific severance and change-in-control benefits.
- Check the company’s director compensation policy and any disclosures of Mr. Singer’s compensation.
- Review Exhibit 99.1, the October 1, 2026 press release, and subsequent filings for further appointment details or board and committee changes.